DOI:

Detection of a necrotic core-rich, highly deformable plaque in an angiographically non-diseased proximal LAD

Gastón A. Rodriguez-Granillo, MD; Raquel del Valle, MD; Jurgen Ligthart, BSc; Patrick W. Serruys*, MD, PhD

Thin-cap fibro atheroma (TCFA) lesions, the most prevalent precursor of plaque rupture, are composed of a lipid-rich necrotic core, a thin-fibrous cap with macrophage and lymphocyte infiltration, decreased smooth muscle cell content and expansive remodeling. Virtual Histology™ uses spectral analysis of intravascular ultrasound (IVUS) radiofrequency data to construct tissue maps that classify plaque into four major components; calcified, fibrous, fibrolipidic and necrotic core regions that are labeled white, green, greenish-yellow and red respectively. Palpography™ evaluates in vivo the mechanical properties of plaque tissue. The local strain is calculated from the radiofrequency traces using cross-correlation analysis and displayed, colour coded, from blue (for 0% strain) through yellow (for 2% strain) via red (Figure 1).

At a defined pressure, soft tissue (lipid-rich) components will deform more than hard (fibrous-calcified) components. Both techniques have been previously validated1,2.

Figure 1a shows an angiographically non-diseased proximal left anterior descending (LAD) artery. IVUS longitudinal reconstruction (Figure 1b) shows diffuse LAD disease. An eccentric mixed plaque that did not compromise the lumen was detected in the proximal LAD (Figure 1c). This segment was further analyzed with Palpography (20 MHz Eagle Eye, Volcano Therapeutics) and Virtual Histology™ (30 MHz Ultracross, Boston Scientific Corp) (Figures 1d and 1e). Despite its innocuous appearance on gray-scale IVUS, highly deformable shoulders with an underlying necrotic core-rich substrate were detected with the aid of strain and compositional imaging.

Although compatible with the presence of a vulnerable plaque, the prognostic value of these findings is currently unknown and needs to be established in large prospective randomized trials. Thus, the patient was discharged on intensive systemic therapy including lipid-lowering agents.

Figure 1. LAD= left anterior descending coronary artery. LCx= Left circumflex coronary artery. LMCA= Left main coronary artery. * Pericardium.

Volume 1 Number 3
Nov 20, 2005
Volume 1 Number 3
View full issue


Key metrics

Suggested by Cory

Research Correspondence

10.4244/EIJ-D-25-00068 Jul 21, 2025
Intracoronary nicardipine to induce hyperaemia
Viscusi M et al

Editorial

10.4244/EIJ-E-25-00023 Jul 21, 2025
DAPT de-escalation post-ACS: a new rule or just a new option? Lessons from the 4D-ACS trial
Cuisset T and Cayla G
free

Research Correspondence

10.4244/EIJ-D-25-00025 Jul 21, 2025
Validation of the pullback pressure gradient in resting conditions
Sakai K et al

Viewpoint

10.4244/EIJ-D-24-00943 Jul 21, 2025
Factor XI inhibition for ACS patients: premises and prospects
Lopes R and Fanaroff A
free

Editorial

10.4244/EIJ-E-25-00031 Jul 21, 2025
Supersaturated oxygen therapy to reduce myocardial infarct size: time to pay attention!
Stone G and Akinmolayemi O
free

Original Research

10.4244/EIJ-D-25-00331 Jul 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
Trending articles
224.25

State-of-the-Art Review

10.4244/EIJ-D-21-00426 Dec 3, 2021
Myocardial infarction with non-obstructive coronary artery disease
Lindahl B et al
free
172.65

Focus article

10.4244/EIJY19M08_01 Jan 17, 2020
EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update
Glikson M et al
free
80.3

State-of-the-Art

10.4244/EIJ-D-24-00066 Apr 21, 2025
Management of complications after valvular interventions
Bansal A et al
free
47.5

Original Research

10.4244/EIJ-D-25-00331 May 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
47.5

Original Research

10.4244/EIJ-D-25-00331 Jul 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved